Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-05

Clinical Trial Update: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MK0869 for major depressive disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK0869 (0869-068)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED